Loading…
Loading…
Exagen will participate in the Canaccord Genuity MedTech & Diagnostics Conference November 11 and the Craig-Hallum Alpha Select Conference November 17
CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2026, before the market opens on Tuesday, November 10, 2026.
What happened Exagen Inc. (NASDAQ: XGN) filed a Form 4 showing Jorey Chernett, a director and 10% owner, bought 14,000 common shares on 2026-10-19. The filing lists the trade as a purchase, and the form was signed on 2026-10-20. The shares changed hands at a weighted average price of $7.46, with purchases ranging from $7.44
Exagen Inc. (NASDAQ: XGN - Get Free Report) CEO John Aballi sold 34,294 shares of the company's stock in a transaction on Friday, October 16th. The stock was sold at an average price of $7.87, for a total value of $269,893.78. Following the transaction, the chief executive officer owned 805,540 shares in the company, valued at
Universal Health Services (NYSE: UHS - Get Free Report) and Exagen (NASDAQ: XGN - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends. Institutional and Insider Ownership 86.0% of Universal Health
Exagen Inc. (NASDAQ: XGN - Get Free Report) has earned an average rating of "Moderate Buy" from the nine analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the
Exagen (NASDAQ: XGN - Get Free Report) and InfuSystem (NYSE: INFU - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability. Earnings and Valuation This table compares Exagen and InfuSystem"s
Exagen (NASDAQ: XGN - Get Free Report) and Gaxos.ai (NASDAQ: GXAI - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends. Valuation and Earnings This table compares Exagen and Gaxos.ai"s